<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956094</url>
  </required_header>
  <id_info>
    <org_study_id>210412-1</org_study_id>
    <nct_id>NCT04956094</nct_id>
  </id_info>
  <brief_title>GGT and Uric Acid to Predict Gestational Diabetes Mellitus</brief_title>
  <acronym>GGTUAGDM</acronym>
  <official_title>Association of Elevated Serum Gamma Glutamyl Transferase (GGT) and Uric Acid at 9-14 Weeks Gestation With the Development of Gestational Diabetes Mellitus (GDM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Carmel Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mount Carmel Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Carmel Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational Diabetes Mellitus (GDM) is a common metabolic complication of pregnancy defined&#xD;
      as new onset hyperglycemia during gestation. GDM conveys significant risk of morbidity and&#xD;
      mortality for both mother and infant. An estimated 268,900 infants were born to mothers with&#xD;
      GDM in the USA, accounting for approximately 6.9% of births. Although individual correlations&#xD;
      have been found between elevated GGT and uric acid levels and later development of GDM, no&#xD;
      research has established and validated combined criteria for GGT and uric acid levels that&#xD;
      would lead to their use in identifying women at high risk of GDM in the first trimester.&#xD;
&#xD;
      Central Hypothesis: Serum GGT and serum uric acid collected between &gt;9-14.0 weeks gestation&#xD;
      will be significantly elevated in women who later develop GDM compared to those who do not.&#xD;
      Combined analysis of serum uric acid and GGT levels within the first trimester allows for&#xD;
      accurate prediction of the development of GDM.&#xD;
&#xD;
      Study population includes women between 9-14 weeks gestation undergoing a standard first&#xD;
      trimester blood draw. Additional blood will be drawn during the standard blood draw to assess&#xD;
      GGT and uric acid levels. Research participants will be tracked afterwards to determine&#xD;
      whether they tested positive for gestational diabetes during the standard testing process&#xD;
      which typically occurs at 24-28 weeks gestation. The data will then be analyzed to estimate&#xD;
      the sensitivity, specificity, positive and negative predictive values of the first trimester&#xD;
      GGT and uric acid tests. The GGT and uric acid levels which maximize the area under the&#xD;
      receiver-operator characteristic curve will be identified.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients diagnosed with gestational diabetes mellitus</measure>
    <time_frame>24-28 weeks</time_frame>
    <description>Diagnosis of gestational diabetes mellitus (GDM) via oral glucose tolerance testing (Carpenter and Coustan criteria)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>First Trimester Prenatal Visit</arm_group_label>
    <description>Women attending an initial first trimester prenatal visit who will be undergoing a standard blood draw.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>GGT/Uric Acid</intervention_name>
    <description>Standard laboratory blood testing for GGT and uric acid levels.</description>
    <arm_group_label>First Trimester Prenatal Visit</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women between &gt; 9 weeks and &lt; 14 and 0 weeks gestation presenting to the OB clinic&#xD;
        for prenatal care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women between &gt; 9 weeks and &lt; 14.0 weeks gestation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of or current diagnosis of type I or type II diabetes mellitus&#xD;
&#xD;
          -  Known liver disease&#xD;
&#xD;
          -  Known kidney disease&#xD;
&#xD;
          -  Known history of or current diagnosis of gout&#xD;
&#xD;
          -  Known history of alcoholism or current alcohol use&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  &lt; 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant Females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>James Dombroski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mount Carmel Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Shaffer, PhD</last_name>
    <phone>614-663-4641</phone>
    <email>Lynn.Shaffer@mchs.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cameron Rink, PhD</last_name>
    <phone>614-546-4518</phone>
    <email>Cameron.Rink@mchs.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mount Carmel Health System</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Shaffer, PhD</last_name>
      <phone>614-663-4641</phone>
      <email>lynn.shaffer@mchs.com</email>
    </contact>
    <contact_backup>
      <last_name>Minden Collamore, DO</last_name>
      <phone>380-898-8808</phone>
      <email>minden.collamore001@mchs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Collamore Minden, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Screening</keyword>
  <keyword>Gamma Glutamyl Transferase</keyword>
  <keyword>Serum Uric Acid</keyword>
  <keyword>Sensitivity</keyword>
  <keyword>Specificity</keyword>
  <keyword>Predictive Value</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data with others. Study data may be requested from the sponsor or investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

